4503N Stock Chart & Stats
$253.00
$0.00(0.00%)
At close: 4:00 PM EDT
$253.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$204.11 - $281.91
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$542.77B
Enterprise Value$4.25T
Total Cash (Recent Filing)$244.70B
Total Debt (Recent Filing)$589.87B
Price to Earnings (P/E)12.3
Beta-0.05
Next Earnings
Nov 04, 2026EPS Estimate
7.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)203.70
Shares Outstanding1,809,663,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.46
Price to Sales (P/S)2.11
P/FCF Ratio8.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$300.24Price Target Upside18.67% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)24.61
Revenue Forecast (FY)$279.61B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow provide internal funding capacity while reducing reliance on external financing. Their close alignment with net income also indicates that reported earnings are translating into cash, supporting financial resilience over the next several quarters.
Healthy ProfitabilityHigh gross margins and solid operating profitability demonstrate meaningful economic value from Astellas’s branded pharmaceutical portfolio. If maintained, this profitability provides room to absorb development costs and commercial investment while preserving substantial earnings power.
Improving Revenue TrendThe acceleration in revenue growth indicates improving commercial momentum after a nearly flat annual period. Sustained top-line expansion would strengthen operating leverage, support reinvestment in the pipeline, and improve the durability of the company’s earnings base.
Bears Say
Profitability VolatilityLarge swings in net margin make earnings less predictable than those of a steady compounder and complicate long-term planning. They suggest that reported profitability can be materially affected by one-offs or product mix, increasing uncertainty around the current run-rate.
Historical Leverage SwingsAlthough current leverage appears manageable, the substantial historical movement in debt-to-equity shows that Astellas’s capital structure has not been consistently stable. Such shifts can affect financial flexibility and make future balance-sheet risk harder to assess.
Cash Conversion ConstraintStrong absolute cash generation is tempered by operating cash flow covering less than half of revenue. This lower conversion rate means that revenue growth does not translate fully into cash, potentially limiting flexibility for investment and other capital needs.
Astellas Pharma News
4503N FAQ
What was Astellas Pharma Inc’s price range in the past 12 months?
Astellas Pharma Inc lowest stock price was $204.11 and its highest was $281.91 in the past 12 months.
What is Astellas Pharma Inc’s market cap?
Astellas Pharma Inc’s market cap is $542.77B.
When is Astellas Pharma Inc’s upcoming earnings report date?
Astellas Pharma Inc’s upcoming earnings report date is Nov 04, 2026 which is in 5 days.
How were Astellas Pharma Inc’s earnings last quarter?
Astellas Pharma Inc released its earnings results on Aug 05, 2026. The company reported $9.493 earnings per share for the quarter, beating the consensus estimate of $6.489 by $3.004.
Is Astellas Pharma Inc overvalued?
According to Wall Street analysts Astellas Pharma Inc’s price is currently Undervalued.
Does Astellas Pharma Inc pay dividends?
Astellas Pharma Inc does not currently pay dividends.
What is Astellas Pharma Inc’s EPS estimate?
Astellas Pharma Inc’s EPS estimate is 7.8.
How many shares outstanding does Astellas Pharma Inc have?
Astellas Pharma Inc has 1,809,663,100 shares outstanding.
What happened to Astellas Pharma Inc’s price movement after its last earnings report?
Astellas Pharma Inc reported an EPS of $9.493 in its last earnings report, beating expectations of $6.489. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astellas Pharma Inc?
Currently, no hedge funds are holding shares in MX:4503N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astellas Pharma Inc
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
4503N Company Deck
4503N Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.View all MX:4503N earnings summaries4503N Stock 12 Month Forecast
Average Price Target
$300.24
▲(18.67% Upside)